Evidence map›Paper›PMID 41050772›Full record

ArticleOncology letters2025

Histone acetyltransferase 1 promotes ovarian cancer progression by regulating cell proliferation and the cell cycle.

Xiao Han, Ling Liu, Jing Li, Yunxiao Zhi, Lanlan Zhao, Limin Yuan, Xuezhe Ouyang, Jie Liu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Xiao HanDepartment of Medical Genetic and Prenatal Diagnosis, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, P.R. China.
Ling LiuDepartment of Medical Genetic and Prenatal Diagnosis, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, P.R. China.
Jing LiDepartment of Medical Genetic and Prenatal Diagnosis, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, P.R. China.
Yunxiao ZhiDepartment of Medical Genetic and Prenatal Diagnosis, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, P.R. China.
Lanlan ZhaoDepartment of Medical Genetic and Prenatal Diagnosis, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, P.R. China.
Limin YuanDepartment of Medical Genetic and Prenatal Diagnosis, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, P.R. China.
Xuezhe OuyangDepartment of Medical Genetic and Prenatal Diagnosis, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, P.R. China.
Jie LiuDepartment of Oncology, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou University, Zhengzhou, Henan 450008, P.R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ovarian cancer (OC) is the most common cause of gynecological cancer-related death. Histone acetyltransferase 1 (HAT1) has generated interest as a potential target for therapy due to it being involved in a variety of diseases, including cancer. However, to the best of our knowledge, the role of HAT1 in OC has not yet been investigated. In the present study, HAT1 was upregulated in OC and the high expression of HAT1 was associated with unfavorable prognosis. The transcription factor forkhead box protein A1 (FOXA1) transcriptionally regulated HAT1 expression. Furthermore, HAT1 knockdown in OC cells significantly suppressed cell proliferation and colony formation. In addition, the inhibition of HAT1 promoted cell cycle arrest, and reduced cyclin-dependent kinase (CDK)2, CDK4 and cyclin E levels in OC cells. Taken together, the present data suggested that HAT1 served an oncogenic role in OC; therefore, HAT1 may represents a new potential therapeutic target in OC treatment.

Indexed as

cell cycleforkhead box protein A1histone acetyltransferase 1ovarian cancertumor growth

Identifiers

PMID41050772
PMCPMC12490291

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.